Axios Re:Cap

Moderna's chief medical officer on its blockbuster vaccine news

Moderna Therapeutics today reported a 94.5% efficacy for its COVID-19 vaccine, which needn't be stored at the same ultra-cold temperatures as does a similar vaccine developed by Pfizer. It also said short-term safety concerns, such as headaches and injection site soreness, self-resolved within days, and that it could have 20 million doses available by year-end. Dan speaks with Moderna chief medical officer Tal Zaks about the new data, distribution, politics, and how it was preparing for this moment even before COVID-19 was discovered.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app. 

Axios Re:Cap is on hiatus until October 2021.